PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

PBRM1, encoding for a subunit of the SWI/SNF complex, is the second most frequently mutated gene in clear cell renal cell carcinoma (ccRCC). Here, the authors show that PBRM1 loss reduces IFNγ-mediated signalling resulting in a less immunogenic tumor microenvironment and that PBRM1 mutations correla...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xian-De Liu, Wen Kong, Christine B. Peterson, Daniel J. McGrail, Anh Hoang, Xuesong Zhang, Truong Lam, Patrick G. Pilie, Haifeng Zhu, Kathryn E. Beckermann, Scott M. Haake, Sevinj Isgandrova, Margarita Martinez-Moczygemba, Nidhi Sahni, Nizar M. Tannir, Shiaw-Yih Lin, W. Kimryn Rathmell, Eric Jonasch
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/2c2ffa7605cd4f008c5d3c780840e07f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:PBRM1, encoding for a subunit of the SWI/SNF complex, is the second most frequently mutated gene in clear cell renal cell carcinoma (ccRCC). Here, the authors show that PBRM1 loss reduces IFNγ-mediated signalling resulting in a less immunogenic tumor microenvironment and that PBRM1 mutations correlate with lack of response to checkpoint inhibitor therapy in ccRCC patients..

Ejemplares similares